Saffron extract benefits: what the clinical trials show, and what they don’t
What three placebo-controlled trials of a saffron extract found for mood and sleep, how to read the results, and what they mean for your product claims.
Interest in saffron for mood, stress and sleep has produced a growing body of placebo-controlled research. For anyone developing a product, it helps to know exactly what those studies tested, and where their conclusions stop.
Three published trials are often cited as background for the category. All three used a saffron extract that is different from Saffrion 42™. They provide background for the category, not evidence for Saffrion 42™ itself.
2017: mood in healthy adults
A double-blind, placebo-controlled study in 128 healthy adults ran for four weeks and compared two doses. Participants taking 28 mg a day showed improved mood scores compared with placebo; at 22 mg a day there was no effect. [1]
2020: sleep quality in adults with poor sleep
In a placebo-controlled trial in adults with poor sleep, 28 mg per day was tested for 28 days; 55 of the 63 participants were analysed. The study reported improvement in sleep measures. [2] For all the sleep trials, see Saffron extract for sleep: what the research shows.
2025: mood in adults with subclinical depressive symptoms
The 2025 trial enrolled 202 adults with subclinical depressive symptoms and compared 28 mg per day with placebo over 12 weeks. The saffron extract showed an advantage on the depression measure, with no difference on the overall secondary measures. [3]
How to read these results
A few points are worth keeping in mind:
- The extract matters. Saffron extracts differ in source, extraction and standardization. Results obtained with one extract cannot simply be transferred to another.
- Outcomes were mixed in places. The 2025 trial found an advantage on its depression measure but no difference on the overall secondary measures. A fair summary mentions both.
- Dose and duration were specific. The 2017 study found an effect at 28 mg but not at 22 mg; the 2020 and 2025 studies used 28 mg per day, for 28 days and 12 weeks respectively. More in Saffron extract dosage: where 30 mg a day comes from.
- Populations were specific. Healthy adults, adults with poor sleep and adults with subclinical symptoms are not the same group.
A dedicated study of Saffrion 42™
Efficacy, tolerability, dose and time to effect for Saffrion 42™ require dedicated data. A clinical study of the extract is planned; results have not yet been reported and are expected in Q1 2027.
Until then, Saffrion 42™ is presented on the strength of its specification and documentation: two measured markers, a controlled trans:cis crocin ratio, batch data and a manufacturing site certified to FSSC 22000 and ISO 22000:2018.
What this means for your claims
Consumer claims for finished products are subject to the regulatory requirements of each target market. Background research on another extract does not, on its own, support claims for a finished product. Your regulatory team will know what applies where you sell.
References
- [1] Kell et al., 2017. Mood in healthy adults, 22 mg and 28 mg a day, 4 weeks. PMID 28735826
- [2] Lopresti et al., 2020. Sleep quality in adults with poor sleep. PMID 32056539
- [3] Lopresti et al., 2025. Mood in adults with subclinical depressive symptoms. PMID 40414301
Statements have not been evaluated by regulatory authorities. Professional content for product development, for B2B use only.
